Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Limitations and Prospects: A Systematic Review

Pancreatic ductal adenocarcinoma is not sensitive to monotherapy with immune checkpoint inhibitors, which might be related to the inhibitory immune microenvironment of pancreatic cancer.